TB-500 vs TB4 Fragment: What's the Difference? (2026 Research Guide)

TB-500 vs TB4 Fragment: Understanding the Difference

One of the most common points of confusion in peptide research is the relationship between TB-500 and TB4 Fragment (also called TB-4 Frag or Frag 17-23). These terms are sometimes used interchangeably — but they are not the same compound.

This article clarifies exactly what each compound is, how they differ, and what the current research indicates about their respective properties.

What Is TB-500?

TB-500 is the synthetic form of thymosin beta-4 (Tβ4), a naturally occurring protein found in virtually all human and animal cells. The full thymosin beta-4 protein consists of 43 amino acids. TB-500 replicates this full-length protein in synthetic form.

TB-500's primary mechanism involves upregulating actin, a protein essential for cell migration, proliferation, and wound healing. By promoting actin polymerization, TB-500 helps the body recruit repair cells to injured tissue faster and more efficiently than normal.

Key properties of TB-500:

Full-length synthetic thymosin beta-4 (43 amino acids)

Promotes actin upregulation and cell migration

Systemic distribution — works throughout the body

Anti-inflammatory properties

Promotes angiogenesis (new blood vessel formation)

What Is TB4 Fragment?

TB4 Fragment — often called TB4 Frag or Frag 17-23 — refers specifically to a short peptide sequence derived from the actin-binding domain of thymosin beta-4. This fragment consists of amino acids 17 through 23 of the full TB-4 sequence.

The fragment was isolated because researchers identified it as the biologically active portion responsible for actin binding. The theory: by isolating the active sequence, you get a more targeted compound with potentially higher bioavailability and a more focused mechanism.

Key properties of TB4 Fragment:

Short-chain peptide (7 amino acids vs. 43)

Contains the active actin-binding domain

Potentially higher bioavailability than full-length TB-500

More targeted mechanism vs. systemic action

Less research data compared to full TB-500

Head-to-Head Comparison

| Property | TB-500 (Full-Length) | TB4 Fragment (Frag 17-23) |
|-----------|---------------------|--------------------------|
| Chain length | 43 amino acids | 7 amino acids |
| Mechanism | Full spectrum Tβ4 activity | Targeted actin-binding |
| Systemic distribution | Yes (body-wide) | More localized |
| Research base | Extensive | Limited |
| Bioavailability | Good | Potentially higher |
| Typical dosage | 2-5mg per injection | 1-2mg per injection |
| Half-life | ~4-5 days | Shorter (less data) |

Which Has More Research Support?

TB-500 (full-length) has significantly more peer-reviewed research than the isolated fragment. The full thymosin beta-4 protein has been studied in the context of cardiac repair, wound healing, corneal injury, neurological recovery, and musculoskeletal injuries across numerous animal studies.

TB4 Fragment (Frag 17-23) has a smaller research base. While the fragment's mechanism is well-understood in vitro, fewer studies have examined its in vivo performance compared to the full-length protein.

Dosage Considerations

TB-500 typical research dosage:

Loading phase: 2-5mg twice weekly for 4-6 weeks

Maintenance: 2-5mg once weekly or biweekly

Administration: Subcutaneous or intramuscular injection

TB4 Fragment typical research dosage:

Generally 1-2mg per injection

Less established protocol due to limited research

Administration: Same as TB-500

All dosage information is provided for research reference only. These compounds are not approved for human use.

Which Should Researchers Choose?

Choose TB-500 if:

You want the most researched option with the largest evidence base

You're looking for systemic effects across multiple tissue types

You want established dosing protocols to follow

Consider TB4 Fragment if:

You're specifically studying the actin-binding mechanism in isolation

You want to compare fragment vs. full-protein activity

You're exploring bioavailability differences

Frequently Asked Questions

Is TB4 Fragment stronger than TB-500?
Not necessarily stronger — more targeted. The fragment isolates one mechanism. The full-length TB-500 has a broader range of documented effects.

Can TB-500 and TB4 Fragment be combined?
Some researchers have combined them, but there's minimal published data on this combination. It's unclear whether there's meaningful synergy or overlap.

Are TB-500 and TB4 the same thing?
No. TB-500 is the synthetic version of the full thymosin beta-4 protein. TB4 Fragment is a short peptide derived from the actin-binding region of that protein. They are related but distinct compounds.

Which is more available from peptide suppliers?
TB-500 (full-length) is more widely available from research peptide suppliers. TB4 Fragment is less commonly stocked.

For related research, see our guides on TB-500 vs BPC-157, TB-500 dosage protocols, and TB-500 mechanism of action.